{"id":44540,"date":"2022-06-01T00:01:33","date_gmt":"2022-05-31T22:01:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/"},"modified":"2022-06-01T00:01:33","modified_gmt":"2022-05-31T22:01:33","slug":"ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/","title":{"rendered":"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes"},"content":{"rendered":"
\n

AURORA, Ontario & DALLAS–(BUSINESS WIRE)–Ovensa Inc. (\u201cOvensa\u201d), a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the market.\n<\/p>\n

\nThe companies will evaluate the synergy of Celanese\u2019s VitalDose\u00ae<\/sup> EVA copolymer delivery technology for drug-eluting implants and Ovensa\u2019s TRIOZAN\u2122 Platform for enhanced RNA, mAb and peptide-based molecule drug delivery. Ovensa and Celanese will focus on formulation development, leveraging each organization\u2019s unique technology and expertise.\n<\/p>\n

\nThe companies are optimistic the collaboration will pave the way for breakthrough therapeutic treatments.\n<\/p>\n

\n\u201cOvensa\u2019s proprietary TRIOZAN\u2122 and targeting ligand platforms opens an exciting pathway into the world of targeted and precision medicines,\u201d said Ovensa\u2019s President and CEO, Mr. St\u00e9phane Gagn\u00e9. \u201cOur platforms focus on complex diseases and other therapeutic areas such as cancer resistance and diseases of the central nervous system. It\u2019s through strategic collaborations with industry leaders like Celanese that we will develop innovative, long-lasting and life-changing therapies to treat some of the world\u2019s most complex diseases.\u201d\n<\/p>\n

\n\u201cCelanese is collaborating with Ovensa to evaluate the use of our VitalDose\u00ae<\/sup> EVA copolymer delivery technology in conjunction with their TRIOZAN\u2122 nanomedicine and targeting ligand platforms to deliver therapeutics to targeted sites in the body allowing for reduced toxicity and superior performance,\u201d said Jeff Haley, Celanese\u2019s Medical\/Pharma Technology & Innovation Leader. \u201cWe are excited to explore this opportunity to advance targeted drug delivery to improve therapeutic outcomes for patients all over the world.\u201d\n<\/p>\n

\nAbout Ovensa Inc.<\/b>\n<\/p>\n

\nOvensa Inc. specializes in the delivery of RNA therapeutics, antibodies and peptides using its TRIOZAN\u2122 nanomedicine and ligand targeting platforms. The company leverages its proprietary Trimethyl Chitosan (TMC) and ligands to overcome drug delivery challenges such as crossing the mucosal and blood-brain barriers, cell targeting and payload internalization. <\/i>For more information visit: <\/i>www.ovensa.com<\/i><\/a>.<\/i>\n<\/p>\n

\nAbout Celanese<\/b>\n<\/p>\n

\nCelanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese’s global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 8,500 employees worldwide and had 2021 net sales of $8.5 billion. For more information about Celanese Corporation and its product offerings, visit <\/i>www.celanese.com<\/i><\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCelanese Contacts:<\/b>\n<\/p>\n

\nI<\/b>nvestor Relations<\/b>
Brandon Ayache
\n
+1 972 443 8509
\n
brandon.ayache@celanese.com<\/a>\n<\/p>\n

\nMedia Relations \u2013 Global<\/b>
W. Travis Jacobsen
\n
+1 972 443 3750
\n
william.jacobsen@celanese.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AURORA, Ontario & DALLAS–(BUSINESS WIRE)–Ovensa Inc. (\u201cOvensa\u201d), a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44540","6":"format-standard","7":"category-industry"},"yoast_head":"\nOvensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AURORA, Ontario & DALLAS–(BUSINESS WIRE)–Ovensa Inc. (\u201cOvensa\u201d), a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-31T22:01:33+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes\",\"datePublished\":\"2022-05-31T22:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/\"},\"wordCount\":479,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/\",\"name\":\"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-05-31T22:01:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/","og_locale":"en_US","og_type":"article","og_title":"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes - Pharma Trend","og_description":"AURORA, Ontario & DALLAS–(BUSINESS WIRE)–Ovensa Inc. (\u201cOvensa\u201d), a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-31T22:01:33+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes","datePublished":"2022-05-31T22:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/"},"wordCount":479,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/","url":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/","name":"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-05-31T22:01:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ovensa-and-celanese-explore-collaborative-innovation-to-advance-precision-drug-delivery-and-therapeutic-outcomes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ovensa and Celanese Explore Collaborative Innovation to Advance Precision Drug Delivery and Therapeutic Outcomes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44540"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44540\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}